On Friday, September 12, 2025, Jefferies shared key insights from 50 investor meetings held over the past two weeks following its thematic note on India’s contract research and development manufacturing organisation (CRDMO) sector. The brokerage said there was broad agreement on a positive outlook for the sector over the next three to five years.
Jefferies highlighted that commentary from companies and their capex expansion plans have reinforced investor confidence in the growth trajectory of the sector. Among stocks, Divi’s Laboratories emerged as the most liked name, though Jefferies noted it is already well owned in portfolios. Other companies that drew strong investor attention included Cohance and Sai Life Sciences.
At the same time, Jefferies flagged some concerns raised by investors, including high volatility in the sector, lofty valuations, and limited transparency. These factors remain watchpoints despite the otherwise constructive medium-term outlook.
Disclaimer: The views and investment recommendations expressed in this article are those of Jefferies. Business Upturn does not endorse or recommend any investment decisions. Investors are advised to consult financial experts before making investment choices.
